HONG KONG – The Korean 2020 KoNECT-MOHW-MFDS International Conference, which is taking place online this year due to the COVID-19 pandemic, faced a challenging start. Technical difficulties hampered some of the early proceeding. However, technology took focus again later in the day in a more positive, with an exploration of artificial intelligence (AI).
HONG KONG – The use of artificial intelligence in drug discovery was back in the spotlight on the last day of the 2020 KoNECT-MOHW-MFDS International Conference, with drug developers pointing out both challenges and possible solutions.
LONDON – The international commission convened in the aftermath of Chinese scientist He Jiankui’s shock announcement of the birth of gene edited twins has set a possible course to approval of heritable gene editing, but said the technique is far from ready for use.
Keeping you up to date on recent developments in oncology, including: New algorithm prioritizes breast cancer patients for surgery, chemotherapy; Oxygen grows tumors but shrinks metastasis chances; ‘Fight or flight’ nervous system helps fight tumors, too; Proton beam therapy available in South Florida.
Researchers at the University of California at San Diego have used RNA-targeted CRISPR to reverse symptoms in an animal model of myotonic dystrophy type 1 (DM1). They reported their findings in the Sept. 14, 2020, issue of Nature Biomedical Engineering.
Keeping you up to date on recent developments in cardiology, including: SCAD vs. plaques in heart attacks; Gut microbiome data may be helpful in routine screening of cardiovascular disease; Some health care professionals use outdated guidelines to screen and diagnose hypertension.
Keeping you up to date on recent developments in neurology, including: New molecule restores lost connections in the spinal cord, brain of mice; Brain stimulation reduces dyslexia deficits; Nerivio wearable piloted for relief in patients with chronic migraine.
Researchers at the Diabetes Institute of the University of Washington and the University of Copenhagen have implicated the brain in the ability of intracranial injections of fibroblast growth factor 1 (FGF1) to restore blood sugar control to diabetic animals for long periods of time.